中文摘要：

目的 探讨血清可溶性间皮素相关蛋白（SMRP）和人附睾蛋白-4（HE4）在卵巢癌早期诊断及病情监测中的临床意义.方法 血清标本取自44例卵巢癌、56例良性肿瘤及40例健康志愿者.ELISA试剂盒测定血清HE4和SMRP,化学发光法测定CA125.结果 卵巢癌组血清CA125、HE4和SMRP高于其他两组.经过理想肿瘤减灭术的卵巢癌术后1 w血清CA125、HE4和SMRP水平明显减低.在诊断效能上,单独检测HE4特异度为100.00%,灵敏度86.36%;SMRP灵敏度77.27%,特异度97.92%;二者与CA125联合检测均可提高灵敏度或特异度.结论 HE4和SMRP补充完善了CA125用于卵巢癌的早期诊断和病情监测,具有较高的临床应用价值.

英文摘要：

Objective To investigate the clinical significance of serum SMRP and HE4 in patients with ovarian epithelial cancer to diagnose earlier and monitor patients＇ condition. Methods The serum samples came from 44 cases with ovarian cancer, 56 cases with ovarian benign tumors and 40 healthy volunteers. The serum CA125 concentration was analyzed by chemiluminescent technique and the serum SMRP and HE4 concentrations were tested by ELISA kit. Results The serum CA125, SMRP and HE4 levels in ovarian cancer group were higher than those of other groups significantly. The serum CA125, SMRP and HE4 levels in patients with ovarian cancer experiencing ideal cytoreductive surgery were significantly decreased at one week after operation. The specificity and sensitivity of serum HE4 were 100% and 86.36% respectively. The sensitivity and specificity of serum SMRP were 77.27% and 97.92% respectively. In unite analysis, the combination CA125 with HE4 or SMRP improved the sensitivity or specificity. Conclusions Serum HE4 and SMRP can compensate the efficacy of CA125 to diagnose ovarian cancer earlier and monitor patients＇ condition, which possess the higher clinical application value.